Twelve to Nothing

If you sell peptides, plan to launch a clinic around them, or buy them from one, mark July 23. That morning, twelve people in a conference room on the FDA's White Oak campus in Silver Spring start a two-day review that the entire cash-pay longevity industry has decided is a turning point. On the table: whether your local compounding pharmacy can legally make BPC-157, TB-500, MOTS-C, KPV, Epitalon, Semax, and a peptide most operators have never heard of, Emideltide.

The optimism is real and it has a source. RFK Jr.'s FDA pulled fourteen peptides off the Category 2 "do not compound" list in February, then sent seven of them to the Pharmacy Compounding Advisory Committee, or PCAC, the panel of pharmacologists and physicians the agency consults when it decides what compounding pharmacies are allowed to make. ^[1] If PCAC recommends a peptide for the 503A bulks list, a licensed pharmacy can eventually make it for you under a prescription. The Peptide List called the referral a near-resurrection. ^[2] OnHealthcare mapped what it would mean for the clinic stack. ^[3] The biohacker forums, predictably, lost their minds.

We think they're all reading the wrong variable.

The question that matters isn't whether PCAC votes yes. It's what a yes is actually worth. And the answer, once you trace how this machine really works, is: a lot less than the price the industry is paying for it.

Three machines, not one

The industry talks about July 23 like it's a single decision. It's three, and they run on different fuel.

Machine one is political, and it already fired. RFK Jr. wants peptides freed. He's said so on Rogan, called the 2023 restrictions overreach, and used his perch at HHS to get them re-reviewed. That's done. That's the part everyone is reacting to. But a referral is a request for a meeting, not a result.

Machine two is scientific, and it's the one people are mistaking for political. PCAC is staffed by working pharmacologists and physicians, not Kennedy appointees. They apply a four-factor test, and the first factor is brutal: is there already an FDA-approved drug that does this job? They have no obligation to vote the way the Secretary wants, and historically they don't vote the way anyone wants. More on their record in a second.

Machine three is bureaucratic, and it's the one nobody is pricing. A PCAC "yes" is a recommendation. To make a peptide legally compoundable, the FDA then has to write and finalize a rule. That process is glacial. Glutathione got a PCAC yes, an 8-5 recommendation, in April 2022. Four years later, the rule still isn't final. ^[6]

Sit with that. The cleanest recent "win" at this committee produced exactly zero legal change in four years. So even if July 23 goes perfectly for the industry, the operators betting on a reopened peptide business in 2026 are betting against the FDA's own published timeline. There is no version of the next eighteen months where a pharmacy can confidently, legally compound BPC-157 because of something that happened in July.

That's the trade. Not "the vote fails." The vote is almost beside the point.

The committee's actual record

Now the vote itself, because the base rate is its own kind of damning.

In 2016, two researchers published a quiet paper in JAMA Internal Medicine that nobody in the peptide world seems to have read. They tracked PCAC's first twelve substance reviews. The committee recommended zero of them for the 503A bulks list. Not a low percentage. Zero. Twelve times the FDA staff recommended against, or PCAC voted against, or both. ^[4]

It hasn't loosened up much since. In the entire history of the 503A bulks process, the FDA has finalized roughly ten substances. ^[5] Total. The committee that the longevity industry is counting on to reopen the peptide market has a decade-long habit of saying no, and a parent agency that takes years to say yes even when the committee says yes first.

Put a number on it. The historical hit rate for a substance going from PCAC review to actually-legal is somewhere between 8 and 15 percent. Walk the longevity forums, read the operator decks, listen to the podcasts, and the implied expectation is closer to 70. That gap is the whole story.

The docket is built to disappoint

Here's the part that should worry anyone who's read the actual meeting notice instead of the hype around it.

Seven peptides, two days. ^[7]

Day one: BPC-157, KPV, TB-500, MOTS-C. Day two: Emideltide (also called DSIP, delta sleep-inducing peptide), Semax, Epitalon.

Now look at the conditions the FDA agreed to evaluate them for:

• BPC-157 for ulcerative colitis
• KPV for wound healing and inflammation
• TB-500 for wound healing
• MOTS-C for obesity and osteoporosis
• Emideltide for opioid withdrawal, insomnia, narcolepsy
• Semax for stroke-related brain injury, migraine, trigeminal neuralgia
• Epitalon for insomnia

None of those are what the industry sells. BPC-157 moves as a tendon-and-gut repair compound, not a colitis drug. TB-500 sells for recovery and lean mass, not wound care. MOTS-C is marketed for mitochondria and "metabolic optimization." Epitalon gets sold as a sleep aid and a longevity-and-telomere play at the same time, depending on the vendor.

The mismatch isn't cosmetic. PCAC runs a four-factor test, and its first question is whether an approved drug already covers the indication on the docket. ^[8] For BPC-157 in ulcerative colitis: yes, several. Mesalamine, infliximab, vedolizumab, and more. For TB-500 in wound healing: yes, there's an approved wound-healing drug and an entire formulary behind it. For MOTS-C in obesity: yes, emphatically, and it's the exact drug class the FDA just spent a year pulling out of compounding. GLP-1s.

If you wanted to engineer a denial, you would do it exactly like this. Put each peptide forward for the one indication where an approved competitor already exists.

The FDA said the quiet part out loud last month. Killing compounded GLP-1s in its April 30 proposed rule, the agency wrote that "supply issues, convenience and cost are not part of FDA's clinical-need analysis." ^[12] That single sentence is the lens PCAC looks through. If an approved drug exists, the case for compounding has to be about a real formulation advantage for a specific patient, not that the compounded version is cheaper or easier to get. Every one of the seven peptides walks in with an approved competitor already standing in the doorway.

The evidence problem, in one peptide

Mismatched indications would be survivable if the science were strong. It isn't, and BPC-157 is the clean example.

The peptide has around 150 published papers. Roughly 90 percent come from one research group in Croatia, led by Predrag Sikiric, going back to the early 1990s. ^[9] No completed Western Phase 2 trial. One registered Phase 1 trial on ClinicalTrials.gov, sponsored by an entity called PharmaCotherapia, withdrawn. ^[10] The lead researcher's group holds undisclosed commercial interests in BPC-157 patents. ^[9]

One research group isn't automatically disqualifying. Plenty of real drugs started that way. But PCAC has rejected substances with far thicker files than this. Domperidone, with decades of clinical use across dozens of countries, got turned down in 2015 on safety grounds, and its evidence base makes BPC-157's look like a pamphlet.

Flynn McGuire, an MD and chief medical resident at the University of Utah, said it plainly in The Peptide List this month: "The amount of hype to evidence is just so skewed, it's crazy." Then the line the FDA staff could lift straight into its briefing memo: "We've cured cancer in mice plenty of times. Haven't done it in people yet." ^[9]

The day-two peptides are worse. Emideltide, Semax, and Epitalon rest mostly on forty years of Russian and Soviet-era research tied to one institute and one scientist, Vladimir Khavinson, with essentially no Western controlled trials that would clear a modern peer-review bar. ^[11] This is the body of evidence the FDA is being asked to bless.

None of this is a knock on whether the peptides work. People feel things on them. It's a statement about what a committee of pharmacologists does when the briefing document in front of them reads like this. They've answered that question twelve times. The answer was no.

What it means for you, depending on who you are

April reshuffled the board before the vote even arrives. On April 7, the FDA fired off seven warning letters to online peptide sellers hiding behind "research use only" labels, stating flatly that the disclaimer is void the moment a product is marketed for human use. ^[15] That ended the gray-market loophole that let vendors ship BPC-157 with dosing charts and a straight face. Stack it on the GLP-1 crackdown, which the FDA finished off by docket entry the same month ^[14], and the market has been squeezed toward one shape: the telehealth-wrapped, pharmacy-partnered, LegitScript-certified operator. Everyone else is running on borrowed time.

Three kinds of operators are left standing, and the vote lands differently on each.

The gray market (SwissChems, Prime Peptides, Orion, the research-peptide sellers) barely feels it either way. They never tried to be legitimate, so a denial keeps their customers locked in and an approval doesn't help a business that runs on price and convenience. Their threat is the FDA's enforcement arm, not a committee vote.

The Protocole pattern, the minimum-viable telehealth wrapper named for the operator that just raised $6M and is about to spawn imitators, is the one with real exposure. ^[16] These are the slick "apply for access" funnels with a five-question intake, a single multi-state clinician on retainer, a partnered pharmacy, and a Stripe account. A denial means their peptide menu stays in the legal gray zone they're already operating in. An approval would have let them stamp "FDA-supported" on the marketing, except per the three-machines problem, that stamp wouldn't be true for years even after a yes. They're pricing in a credential they won't be able to use.

Full telehealth (Hims, Ro, Henry Meds, Eucalyptus) mostly shrugs. Their money is in GLP-1s, which they've already moved onto Novo and Lilly distribution deals. They were never going to build a business on Russian sleep peptides. The only July 23 question that touches them is whether the cheaper Protocole funnels start eating their customer acquisition.

For the compounding pharmacies themselves, the gap between zero approvals and two is enormous in the press release and trivial in the bank account. Two narrowly-approved peptides, hedged with restrictions, arriving via a rule that won't finalize until 2028 or later, do not rebuild a revenue line. It's the GLP-1 story again: a legal pathway that exists on paper and nowhere a CFO can spend it.

The uncomfortable part: the real winners of the compounded-peptide boom were never the compounders. They were the gray-market suppliers who built clean logistics, batch-tested their product, and ran discount codes like a DTC brand. That demand isn't disappearing. It's migrating to the telehealth funnels. July 23 doesn't change where the money flows. It only changes how respectable the receiving end gets to look.

What we'd watch before the vote

The docket closes July 22 at 11:59 PM Eastern; comments in by July 9 reach the committee in advance. ^[13] Five things worth tracking:

The FDA staff briefing documents. These post 7 to 14 days before the meeting, and they are the single best predictor of the outcome. The staff memo is the script the vote tends to follow. When it lands, our scenario weights should move more than on any other signal.

The Alliance for Pharmacy Compounding and the Outsourcing Facilities Association filings. Both represent compounders. Whether they argue narrow medical necessity or push for broad inclusion tells you how the industry itself is reading the room.

Patient-advocacy submissions. PCAC is occasionally moved by a credible patient or rare-disease filing where it's unmoved by industry lobbying. One serious advocacy comment on any of the seven would shift the math.

Public-equity tone. Hims and Ro aren't exposed to the peptide vote directly, but if their analyst calls start name-checking PCAC optimistically, the industry's read is running hotter than ours. Silence confirms ours.

Which small compounders go quiet. Empower Pharmacy, BPI Labs, and others will position publicly before July 23. The ones that suddenly stop talking are the ones planning for a no.

Where we could be wrong

We'll say the number out loud: we put the odds that we're meaningfully wrong here at 25 to 30 percent.

The bull case is real. This is the FDA that chose to refer these peptides, under a Secretary who uses them personally and wants them through. A motivated agency can lean on a staff memo. A committee can read the political weather. If the briefing documents come in soft and PCAC recommends four or five of the seven, the vote itself will look like a regime change, and the "twelve to nothing" base rate will look like yesterday's pattern.

But notice what even that scenario doesn't do. It doesn't finalize a rule. It doesn't approve a drug. It doesn't give a single pharmacy legal cover to compound BPC-157 in 2026. The three-machines problem survives a friendly vote completely intact. To actually lose this trade, you don't just need PCAC to say yes. You need the FDA to then do something it has never once done: fast-track a 503A bulks rule to finalization in months instead of years. Bet on that if you want to. We won't.

We'd rather be on record now and graded in public than vague today and clever in hindsight. The post-vote issue, last week of July, will hold every word of this to account.

The call from where we sit: July 23 disappoints the people who turned it into a catalyst. The operators who built around an imminent FDA blessing spend the back half of 2026 quietly readjusting. The ones who built assuming the regulatory door stays mostly shut look, in retrospect, like the smart money. The evidence on the docket only points one way.

What we don't know

The FDA staff briefing documents aren't posted yet. They're the highest-value signal in this whole analysis, and when they land our weights should move.

We can't size the gray market precisely. Nobody can from public data; the honest sellers don't publish revenue and the dishonest ones lie.

And we genuinely don't know how the tension between what RFK Jr. wants and what the FDA's career scientists recommend resolves inside the building. The two layers don't always agree, and we're reading the same public record you are.

If you operate in this space and see it differently, tell us. The tip line is tips@compounded.health, anonymous and encrypted on request. Corrections, as always, go to corrections@compounded.health.